Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

83 results about "Mass screening" patented technology

Mass Screening. Mass screening is being considered, especially where the tumor is common such as in parts of South America and Asia.

Cerebrovascular abnormality analysis method based on transcranial Doppler ultrasound image

The invention discloses a cerebral vessel anomaly analysis method based on a transcranial Doppler ultrasound image, which comprises the steps of TCD image data acquisition, TCD image space-time filtering preprocessing, automatic blood vessel positioning and three-dimensional modeling, the method comprises the steps of generating a standardized blood vessel segmentation model and a static blood vessel network graph, extracting blood flow quantitative parameters and spectrum qualitative features, analyzing multi-blood vessel space correlation features through a graph attention network, performing primary classification on blood flow states, performing secondary classification on lesion types, making risk grading judgment, generating intervention suggestions and outputting a structured report. By setting an automatic parameter measurement method, the manual operation time of doctors is shortened, and the speed and accuracy of lesion judgment are improved through automatic standardization judgment of frequency spectrum forms and association of multi-dimensional parameters. Meanwhile, the experience requirement of doctors for judging the lesion is reduced, and reference is conveniently provided for batch screening of primary hospitals.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Biomarker combination and application thereof in IDH-1 gene mutation detection

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker combination and application thereof in IDH-1 gene mutation detection. The biomarker combination comprises one or more of the following lipid metabolites: a third component of high-density lipoprotein-triglyceride, a fourth component of high-density lipoprotein-triglyceride, high-density lipoprotein-triglyceride, lactic acid and sphingomyelin. Whether a glioblastoma patient carries IDH-1 gene mutation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and suitable for large-scale screening, and a new solution is provided for clinical patient diagnosis.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY +1

Colorectal cancer plasma circulating microbial marker, reagent, kit and application thereof

The invention discloses a colorectal cancer plasma circulating microbial marker, a reagent, a kit and application thereof, and belongs to the technical field of biomedical detection. The plasma circulating microbial marker for colorectal cancer comprises alternaria alternata, alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous The colorectal cancer plasma circulating microbial marker can be used for early screening of colorectal cancer, has relatively high sensitivity and specificity, and remarkably improves the accuracy and reliability of detection; the limitation of traditional ctDNA detection is broken through, and the detection rate of early colorectal cancer is improved. The colorectal cancer plasma circulating microbial marker in a colorectal cancer plasma sample is detected through low-depth whole genome sequencing, the requirement for depth in an experiment is reduced, the cost can be greatly reduced while high sensitivity and specificity are guaranteed, and the method is more suitable for large-scale screening.
Owner:BEIJING XUTENG GENE TECHNOLOGY CO LTD

Biomarker combination for radiotherapy prognosis evaluation of liver cancer patient and application of biomarker combination

The invention discloses a biomarker combination for radiotherapy prognosis evaluation of liver cancer patients and application of the biomarker combination. The biomarker combination is composed of IDPN, VLCH, V5TG, VLFC, V1CH, V1FC and V4FC. The biomarker combination provided by the invention is used for evaluating the radiotherapy prognosis of the liver cancer patient, not only is high in accuracy and good in sensitivity and specificity, but also has the advantages of small trauma to the patient, convenience in sampling, low detection cost and the like, and is suitable for large-scale screening.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY

Immunosensor for detecting confinement composite nano-enzyme enhanced electrochemiluminescence of tumor necrosis factors as well as construction method and application of immunosensor

The invention discloses a confinement composite nano-enzyme enhanced electrochemiluminescence immunosensor for detecting tumor necrosis factors and a construction method and application of the immunosensor. The immunosensor is a three-electrode system, and liquid to be detected contains luminol; wherein the working electrode is obtained by covalently immobilizing a tumor necrosis factor specific antibody after an SNF epoxy modified electrode is subjected to confinement of Ni (OH) 2-CeO2 composite nano-enzyme and then closing a non-specific site. The Ni (OH) 2-CeO2 composite nano-enzyme is confined in a nano-channel, the Ni (OH) 2-CeO2 composite nano-enzyme and the nano-channel can synergistically accelerate the process of an oxygen reduction reaction, the modification stability of the nano-enzyme is effectively improved, and a formed immune complex causes increase of interface resistance and steric hindrance of a sensing electrode to cause signal reduction; therefore, high-sensitivity detection of the tumor necrosis factor is realized, and the constructed sensor has the advantages of low detection limit, wide detection range and the like, and is very suitable for being widely applied to the fields of auxiliary clinical diagnosis, large-scale screening, health monitoring and the like.
Owner:ZHEJIANG SCI-TECH UNIV

Neurology index prediction system and method

The invention discloses a neurology index prediction system and method. The method comprises the following steps: firstly, collecting case data of a neurology patient; processing the collected case data to form test data; meanwhile, constructing a neurology index prediction model; inputting test data into the neurology index prediction model for training; and finally, inputting the case data which does not participate in training into the trained neurology index prediction model, and generating a patient neurology disease prediction result from the case data which does not participate in training through the neurology index prediction model. The prediction comprehensiveness is improved through multi-modal data fusion, the detection sensitivity of early functional abnormalities is remarkably improved, the prediction model is more accurate and stable through high-dimensional nonlinear correlation mining and model generalization optimization, non-invasive low cost and clinical interpretability can be considered, invasive detection or high-cost image equipment is not needed, and the method is suitable for large-scale popularization and application. The method is suitable for large-scale screening of basic medical institutions.
Owner:THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV

Synthesis of Toluidine blue O and a kit for mucosal application

The present invention describes synthesis of Toluidine blue O for a formulation to be used for screening and biopsy site identification in oral cancer. The invention discloses two formulations and a m
Owner:PANDA SWAGATIKA

Method for generating depression diagnosis dialogue dataset, electronic device and storage medium

An embodiment of the present invention provides a method for generating a depression diagnosis dialogue dataset. The method includes: initiating a dialogue with a real population including depression patients based on the clinical criteria for depression diagnosis to generate a patient portrait of the real population; simulating the depressive outpatient dialogue records between the patient role and the doctor role based on the patient portrait; supervising and filtering the depressive outpatient dialogue records to obtain a depression diagnosis dialogue dataset that meets the clinical criteria. The depression diagnosis dialogue dataset collected in the embodiments of the present invention is of great significance for studying the end-to-end depression consultation dialogue and symptom-based depression diagnosis. The dialogue system also plays a very important role in the large-scale screening and follow-up of depression, and can effectively help alleviate the problems caused by the imbalance of medical resources.
Owner:AISPEECH CO LTD

Application of sEVs membrane protein detection in breast cancer drug resistance early warning product

The invention discloses application of sEVs membrane protein detection in breast cancer drug resistance early warning products, and belongs to the field of biomedicine. A plurality of breast cancer drug resistance associated sEVs membrane proteins are selected to form the combined marker, so that the detection accuracy can be effectively improved. By applying the antibody, the primer and the probe designed by the invention and combining the design of four-layer cascade amplification and multi-target conjoint analysis, four-round signal amplification can be completed, the limitation of a traditional single-target detection method is effectively broken through, the detection sensitivity is remarkably improved, the detection time is shortened, the detection cost is reduced, and the possibility is provided for clinical large-scale screening.
Owner:JIANGNAN UNIV

Cancer detection assistance method and detection kit

PendingCN121713068ADisease diagnosisBiological testingLiposarcomaTongue Carcinoma
The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.
Owner:NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST

Serum metabolite-based colorectal adenoma screening method

The invention discloses a colorectal adenoma screening method based on serum metabolites, and belongs to the field of biomedical detection. The method comprises the steps of serum sample pretreatment, instrument analysis, quantitative analysis and prediction model construction, after 15-25 [mu] L of a serum sample is treated, 41 serum metabolites, age, gender and BMI are combined, and a LightGBM model is used for predicting the disease probability and performing layered suggestion. The kit fills up related gaps, has the advantages of non-invasiveness, high sensitivity and specificity, portability, high efficiency, low cost and the like, and is suitable for large-scale screening.
Owner:FUDAN UNIVERSITY

Multi-dimensional tumor marker joint detection device and use method thereof

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.
Owner:SUZHOU HONGYUAN BIOTECH CO LTD

A clinical whole-exon non-invasive prenatal monogenic disease detection method based on second-generation sequencing

The application discloses a clinical whole-exon non-invasive prenatal monogenic disease detection method based on second-generation sequencing, relates to the field of non-invasive prenatal diagnosis, and comprises the following steps: obtaining fetal free DNA in peripheral blood of a pregnant woman; constructing a sequencing library with a UMI molecular tag; adopting UMI error correction, Bayesian fetal fraction estimation, maternal background filtering, high-depth redundant verification and parent cross verification, constructing a capture Panel covering more than 5,000 genes and encrypting AD gene probes, and adapting to a domestic sequencing platform to realize accurate identification of new dominant mutations, eliminate noise interference such as maternal clonal hematopoiesis, improve detection accuracy of low fetal fraction samples, do not need invasive sampling and depend on a proband family, reduce detection complexity and cost, and be suitable for large-scale screening, so that a complete technical scheme is provided for non-invasive prenatal screening of monogenic dominant genetic diseases and domestic platform clinical transformation is promoted.
Owner:MATERNAL & CHILD HEALTH HOSPITAL OF HUBEI PROVINCE

Screening of individuals for a respiratory disease using artificial intelligence

An artificial intelligence-based system and method for scalable screening of individuals for respiratory infection, such as COVID-19. The system is trained to distinguish distinct latent features of cough sounds produced by a COVID-19 infected person from cough sounds produced by patients suffering from any other respiratory infection or involuntary cough sounds produced by a healthy person. Cough sound samples from individuals can be remotely collected and evaluated by the system for likelihood of the COVID-19 infection. Additionally, images of affected body parts, biomarkers, metadata, and other respiratory sound samples can also be used for screening.
Owner:AI4LYF LLC

Cancer examination support method and examination kit

PCT designated stage expiredWO2025041833A1Disease diagnosisBiological testingLiposarcomaOncology
It has been found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. Gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected by using a reagent that specifically detects the SDF4. The measurement of the SDF4 in the body fluid sample is an examination method capable of detecting various types of cancer with a single examination, and can be used for mass screening for cancer. Moreover, early-stage cancer can also be detected with good sensitivity and specificity, and thus cancer can be discovered at an early stage, leading to treatment.
Owner:NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST

A method for detecting urine small extracellular vesicle PLA2R1 membrane protein for distinguishing membranous nephropathy

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.
Owner:XIAMEN UNIV

Bladder cancer early screening method based on plain scanning CT and MRI time sequence fusion

The invention discloses a bladder cancer early screening method based on plain-scan CT and MRI time sequence fusion, which realizes high-precision lesion recognition and positioning under the condition of low-dependence enhanced scanning through knowledge distillation and bimodal feature fusion. The method comprises the following steps: constructing a multi-modal data set including plain scanning, arteriovenous phase enhanced CT and MRI; a key frame sparse annotation and linear interpolation complementation strategy is adopted to reduce the annotation cost; performing preprocessing such as window level adjustment, normalization and zooming on the image; a CT / MRI recognition and positioning network is constructed, each sub-network comprises a 2D positioning branch and a 3D classification branch, and the characterization capability of plain scanning data is enhanced through a teacher-student knowledge distillation mechanism; and finally, integrating the bimodal information through a feature fusion module, and outputting a classification and positioning result. According to the method, time sequence consistency and modal consistency constraints are introduced, the recognition robustness of small focus and unclear boundary areas is improved, the manual film reading burden is remarkably reduced, the screening efficiency and safety are improved, and the method is suitable for early large-scale screening scenes of bladder cancer and has important clinical popularization value.
Owner:ZHEJIANG UNIV

Synthesis of toluidine blue o and a kit for mucosal application

The present invention describes synthesis of Toluidine blue O for a formulation to be used for screening and biopsy site identification in oral cancer. The invention discloses two formulations and a method of delivery of the said formulations via a kit. The method described is a reproducible method of synthesis of pharmaceutical grade Toluidine blue O of acceptable purity and good colorimetric value. The present invention also discloses a kit that includes one formulation of a cleaning solution containing an organic acid and another formulation that is a vital stain formulation. The kit is packaged as a dual chamber sprayer having two pump dispensers, that facilitates ready to use, convenient dental chair side delivery, and allows mass screening.
Owner:PANDA SWAGATIKA

Serum metabolic biomarkers and kit for detecting drug-resistant tuberculosis

A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.
Owner:ZHEJIANG SUKEAN PHARMACEUTICAL CO LTD

Test strip for detecting Alzheimer's disease and application thereof

The invention discloses a test strip for detecting Alzheimer's disease and application thereof, the test strip adopts a colloidal gold-horseradish peroxidase compound labeling technology, the detection sensitivity is remarkably improved through enzyme signal amplification, and two key AD biomarkers p-Tau-181 and A beta 1-42 in blood can be synchronously detected. The test strip comprises a sample pad, a marking pad, a nitrocellulose membrane and absorbent paper, wherein the nitrocellulose membrane is provided with two detection lines (T1 and T2) for capturing p-Tau-181 and A beta1-42 respectively and a quality control line (C). The kit is high in sensitivity, rapid in detection, simple and convenient to operate, low in cost and suitable for primary medical treatment and large-scale screening scenes, and has important value in early diagnosis, popularization, prevention and control of the Alzheimer's disease.
Owner:SHAOXING SEVENTH PEOPLES HOSPITAL

Lipid metabolite combination for early diagnosis marker of vkh and application thereof

PendingCN122449015ALipidomeMetabolite
The present application relates to the technical field of biological medicine, in particular to a lipid metabolite combination for early diagnosis of VKH and application thereof, by obtaining plasma samples of patients with initial acute stage (early stage) VKH syndrome and healthy controls, and constructing sample-full lipid quantitative expression matrix, screening differential lipids through PCA unsupervised analysis and OPLS-DA supervised model, further screening lipids with high diagnostic performance by using elastic net logistic regression model, finally obtaining a diagnostic marker combination composed of 25 lipid metabolites, solving the technical problems of existing VKH diagnosis technology, such as invasiveness, insufficient sensitivity and stability of protein marker detection, limited diagnostic efficiency, lack of systematicness and standardized process in lipidomics research, achieving the effect of non-invasive, efficient, high sensitivity and high specificity of early auxiliary diagnosis of VKH syndrome, and providing objective and reliable technical means for precise identification of atypical cases and large-scale clinical screening.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY

CSF-1 biomarker for diagnosis of diabetic foot and application of CSF-1 biomarker

PendingCN119086931AAccurate detection of expression levelshigh sensitivityBiological testingDiabetic footMedical diagnosis
The invention discloses a CSF-1 biomarker for diagnosis of diabetic foot and application of the CSF-1 biomarker, and belongs to the technical field of medical diagnosis. The invention provides a high-sensitivity and high-specificity diabetic foot diagnosis method. Through the Olink Proteomics technology, the expression level of CSF-1 in diabetic foot patients can be accurately detected, a potential large-scale screening index is provided for clinic, the accuracy of early diagnosis is improved, and the operation process is simplified.
Owner:CHANGSHA CENT HOSPITAL

Plasma lipid marker for diagnosing Alzheimer's disease and application thereof

The invention belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and application thereof, and the plasma lipid marker is selected from one or more of PA 16: 016: 0, PE O-18: 022: 4, PE P-16: 022: 4, TG 46: 4-FA18: 2, LPC 22: 4, ChE 22: 4, ChE 22: 0, ChE 20: 2, ChE 18: 0, ChE 16: 1 and ChE 20: 1. According to the present invention, the area under the curve (ROC) of the Alzheimer's disease subject diagnosed by the 11 plasma lipid markers is up to 1, and the Alzheimer's disease patient and the healthy subject can be accurately distinguished; detection can be completed through a venous blood collection method, a traditional cerebrospinal fluid collection method with higher trauma is replaced, and low-trauma and low-cost large-range crowd screening of the Alzheimer's disease is facilitated.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

Bioelectrodes

ActiveJP1813163SSmall holePhysics
The article of the present design is formed in a truncated cone shape with a through hole in the center and can be used primarily as a bioelectrode for mass screening. It has a bulge on the periphery of the front side and a protrusion rising from the top surface, which can be used as a grip when attaching or detaching. In particular, the grip protruding from the periphery enhances its tensile strength. The central through hole is also formed with an expanded diameter, and the bottom is formed as a small hole with a narrowed inner diameter, so the central through hole has a bottom.
Owner:I MEDEX COLTD

An exosomal characteristic protein composition for diagnosing HIV-related asymptomatic neurocognitive disorders and its application

This invention discloses an exosome characteristic protein composition for diagnosing HIV-related asymptomatic neurocognitive impairment (ANI), comprising the following characteristic proteins: DSCAM, IGF1, CAMK2D, UPF1, ALDH2, and EIF5A. Compared with non-ANI individuals, the relative abundance of DSCAM and IGF1 is increased in ANI individuals, while the relative abundance of CAMK2D, UPF1, ALDH2, and EIF5A is decreased. This exosome characteristic protein composition has the following advantages: (1) high diagnostic accuracy, comprehensively covering the core pathways of ANI pathological mechanisms, and accurately identifying ANI patients; (2) high specificity, clearly reflecting the specific expression patterns of exosome proteins in ANI patients, thereby effectively distinguishing ANI from NCI and healthy individuals; (3) non-invasive and convenient, based on peripheral plasma testing, improving subject compliance, and suitable for large-scale screening and long-term follow-up; (4) easy clinical translation: the kits prepared for the above exosome characteristic proteins are easy to operate, can be mass-produced and used, and can be implemented in hospitals and disease control centers at all levels, making them suitable for widespread application.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV

Method for constructing lipid droplet aggregation type microglial cell model based on AD plasma induction

The invention provides a construction method of an Alzheimer's disease individual plasma-induced lipid droplet aggregation type microglial cell model. The construction method comprises the following step: forming lipid droplet aggregation in Alzheimer's disease individual plasma-induced microglial cells. The invention provides a novel construction method of the lipid droplet aggregation type microglial cell model, the construction method is simple to operate and low in cost, and the plasma of a patient with Alzheimer's disease is not required to be fresh collected plasma. The kit has the advantages that the kit can be separated and then subjected to cryopreservation and batch detection at the temperature of-80 DEG C, the kit is suitable for early-stage large-scale screening of the Alzheimer's disease, and in addition, the defect that an existing Alzheimer's disease diagnosis model only pays attention to an ATN (beta amyloid position) system can be overcome.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)

Hand bone image analysis method based on feature extraction and related equipment

The present application provides a hand bone image analysis method and related equipment based on feature extraction. First, a trained main neural network extracts the global features of the patient's hand bone image to obtain a global feature vector, and then extracts the key area features by selecting the key area to obtain the key area feature vector, and then splices the global feature vector and the key area feature vector to obtain a splicing vector; the trained main neural network diagnoses the global feature vector, the key area feature vector and the splicing vector respectively to obtain a global diagnosis result, a key area diagnosis result and a splicing diagnosis result, and then performs a comprehensive diagnosis on the hand bone image based on the above three diagnosis results to determine whether the patient suffers from Kashin-Beck disease. The method provided in the present application ensures the efficiency and accuracy of Kashin-Beck disease diagnosis, meets the needs of large-scale screening of patients with Kashin-Beck disease, and solves the problem of low efficiency in manually judging whether an image is sick during large-scale screening in related technologies.
Owner:BEIJING UNIV OF POSTS & TELECOMM

SLAMF1 biomarker for diagnosis of diabetic foot and application of SLAMF1 biomarker

The invention discloses an SLAMF1 biomarker for diagnosis of diabetic foot and application of the SLAMF1 biomarker, and belongs to the technical field of medical diagnosis. The invention provides a high-sensitivity and high-specificity diabetic foot diagnosis method. Through the Olink Proteomics technology, the expression level of the SLAMF1 in diabetic foot patients can be accurately detected, a potential large-scale screening index is provided for clinic, the accuracy of early diagnosis is improved, and the operation process is simplified.
Owner:CHANGSHA CENT HOSPITAL

Chemiluminescence detection kit for soluble growth stimulation expression factor 2 and preparation method of chemiluminescence detection kit

The invention provides the high-sensitivity and high-stability sST2 chemiluminescence detection kit, by optimizing a magnetic particle coating process and an acridinium ester labeling purification process, the wide linear detection range of 4-1024ng / mL and the excellent performance that the inter-batch CV is less than or equal to 10% are realized, and the kit is suitable for clinical large-scale screening and accurate diagnosis.
Owner:EACHY BIOPHARMACEUTICALS CO LTD

Cervical vertebra quantitative detection method based on cervical vertebra image

The invention discloses a cervical vertebra quantitative detection method based on a cervical vertebra image, and the method comprises the steps: obtaining an original cervical vertebra image, and carrying out the preprocessing of the original cervical vertebra image, and obtaining a standardized pixel value; extracting a prediction key point set from the standardized pixel values; according to a two-dimensional Euclidean distance between a predicted key point in the predicted key point set and a real key point, determining an average regression error of the predicted key point based on the two-dimensional Euclidean distance; training and optimizing the predicted key point set to obtain a target key point set; determining a heat map according to the target key points in the target key point set, the coordinates of the original pixel points and the standardized pixel values; and determining a visual overlay graph according to the heat map and the standardized pixel value. The structure parameters, the heat map and the visual overlay map obtained by the application can assist a doctor in quickly judging cervical vertebra diseases to obtain a diagnosis result, the burden of the doctor is greatly reduced, various cervical vertebra related diseases are diagnosed at the same time, and the method is suitable for large-scale screening and daily monitoring.
Owner:DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE